







an Open Access Journal by MDPI

Measles-Mumps-Rubella-Varicella Vaccination

Guest Editor:

Prof. Dr. Silvio Tafuri

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy

Deadline for manuscript submissions:

closed (1 February 2021)

Message from the Guest Editor

Dear Colleagues,

According to the Global Vaccine Action Plan, measles and rubella are targeted for elimination in five WHO Regions by 2020. This goal, established in 2015, has been postponed and probably will be delayed, according to the actual world epidemiological scenario.

Global measles deaths have declined from 550,100 deaths in 2000 to 89,780 deaths in 2016. Furthermore, we noted a very important resurgence of this disease; WHO statistics showed over 112,000 confirmed measles cases globally in the first 4 months of 2019. Europe has also seen a 300% increase in measles infection, with Italy and the German state of Brandenburg ordering mandatory vaccinations.

Prof. Silvio Tafuri Guest Editor







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us